Improved lipid profile in hyperlipidemic patients taking vaccinium arctostaphylos fruit hydroalcoholic extract: A randomized double-blind placebo-controlled clinical trial

Phytotherapy Research

Volumn 28, Issue 3, 2014, Pages 432-436

  Kianbakht, S ^a,b   Abasi, B ^c   Hashem Dabaghian, Fataneh ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Research Institute of Medicinal Plants Research Complex of Iranian Academic Center for Education   (Iran)

^c Diabetes Clinic   (Iran)

Author keywords

anti hyperlipidemic; Caucasian whortleberry; hyperlipidemia; Vaccinium arctostaphylos

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHOCYANIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VACCINIUM ARCTOSTAPHYLOS EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG SYNTHESIS; ERICACEAE; FEMALE; FRUIT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYSICAL ACTIVITY; POWDER; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VACCINIUM ARCTOSTAPHYLOS; WHORTLEBERRY;

VACCINIUM ARCTOSTAPHYLOS; VACCINIUM MYRTILLUS;

ANTI-HYPERLIPIDEMIC; CAUCASIAN WHORTLEBERRY; HYPERLIPIDEMIA; VACCINIUM ARCTOSTAPHYLOS;

ADULT; ANTHOCYANINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FRUIT; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; IRAN; MALE; MIDDLE AGED; PLANT EXTRACTS; TRIGLYCERIDES; VACCINIUM; YOUNG ADULT;

EID: 84895810848     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5011     Document Type: Article

References (28)

1. Abidov M, Ramazanov A, Jimenez Del Rio M, et al,. 2006. Effect of blueberin on fasting glucose, C-reactive protein and plasma aminotransferases, in female volunteers with diabetes type 2: double-blind, placebo controlled clinical study. Georgian Med News 141: 66-72.
2. Backes JM, Gibson CA, Howard PA,. 2005. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 1: 317-331.
3. Basu A, Rhone M, Lyons TJ,. 2010. Berries: emerging impact on cardiovascular health. Nutr Rev 68: 168-177.
4. Bays H, Stein EA,. 2003. Pharmacotherapy for dyslipidemia-current therapies and future agents. Expert Opin Pharmacother 4: 1901-1938.
5. Burnett JR, Watts GF,. 2007. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets 11: 181-189.
6. Davidson MH, Toth PP,. 2004. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 47: 73-104.
7. de Pascual-Teresa S, Moreno DA, Garcia-Viguera C,. 2010. Flavanols and anthocyanins in cardiovascular health: a review of current evidence. Int J Mol Sci 11: 1679-1703.
8. Eckel RH,. 2010. Approach to the patient who is intolerant of statin therapy. J Clin Endorinol Metab 95: 2015-2022.
9. Francis FJ,. 1982. Analysis of anthocyanins. In Anthocyanins as food colors, Markakis P, ed. Academic Press: New York; 182-205.
10. Fugh-Berman A,. 2000. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol 3: 24-32.
11. Fung EC, Crook MA,. 2012. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther 30: e212-e218.
12. Gotto AM Jr, Moon JE,. 2012. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 110: 3A-14A.
13. Haynes R, Jiang L, Hopewell JC, et al,. 2013. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34: 1279-1291.
14. Huang TH, Kota BP, Razmovski V, et al,. 2005. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol 96: 3-14.
15. Kowalczyk E, Krzesinski P, Kura M, et al,. 2003. Anthocyanins in medicine. Pol J Pharmacol 55: 699-702.
16. Latti AK, Kainulainen PS, Hayirlioglu-Ayaz S, et al,. 2009. Characterization of anthocyanins in Caucasian blueberries (Vaccinium arctostaphylos L.) native to Turkey. J Agric Food Chem 57: 5244-5249.
17. Mazza GJ,. 2007. Anthocyanins and heart health. Ann Ist Super Sanita 43: 369-374.
18. Seymour EM, Singer AA, Kirakosyan A, et al,. 2008. Altered hyperlipidemia, hepatic statosis, and hepatic peroxisome proliferator-activated receptors in rats with intake of tart cherry. J Med Food 11: 252-259.
19. Seymour EM, Tanone II, Urcuyo-Llanes DE, et al,. 2011. Blueberry intake alters skeletal muscle and adipose tissue peroxisome proliferator-activated receptor activity and reduces insulin resistance in obese rats. J Med Food 14: 1511-1518.
20. Tapsell LC, Hemphill I, Cobiac L, et al,. 2006. Health benefits of herbs and spices: the past, the present, the future. Med J Aust 185: S4-24.
21. Tavintharan S, Kashyap ML,. 2001. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 3: 74-82.
22. Tenenbaum A, Fisman EZ, Motro M, et al,. 2008. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 45: 127-153.
23. Wallace TC,. 2011. Anthocyanins in cardiovascular disease. Adv Nutr 2: 1-7.
24. Wei X, Wang D, Yang Y, et al,. 2011. Cyanidin-3-O-β-glucoside improves obesity and triglyceride metabolism in KK-Ay mice by regulating lipoprotein lipase activity. J Sci Food Agric 91: 1006-1013.
25. Wierzbicki AS, Hardman TC, Viljoen A,. 2012. New lipid-lowering drugs: an update. Int J Clin Pract 66: 270-280.
26. Zargari A,. 1997. Medicinal Plants, Vol. 4, 4th edn. Tehran University Publications: Tehran.
27. Zeng Y, Song JX, Shen XC,. 2012. Herbal remedies supply a novel prospect for the treatment of atherosclerosis: a review of current mechanism studies. Phytother Res 26: 159-167.
28. Zhu Y, Xia M, Yang Y, et al,. 2011. Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. Clin Chem 57: 1524-1533.